Structure via PubChem · Public domain (PubChem)
rapastinel
Sign in to saveRapastinel () (former developmental code name GLYX-13) is a novel antidepressant that was under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant depression. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide that acts as a novel and selective modulator of the NMDA receptor. The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to enhance NMDA receptor-mediated signal transduction and synaptic plasticity.
Chemical data
- Formula
- C18H31N5O6
- Molecular weight
- 413.5 g/mol
- IUPAC name
- (2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
- SMILES
- C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
- InChIKey
- GIBQQARAXHVEGD-BSOLPCOYSA-N
- XLogP
- -2.8
- Polar surface area
- 179 Ų
- H-bond donors
- 5
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Protein
- Indications
- obsessive-compulsive disorder, major depressive disorder
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 413.227
Show 5 more facts
- canonical SMILES
- CC(C(C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)N)N)O
- chemical formula
- C₁₈H₃₁N₅O₆
- isomeric SMILES
- C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
- Commons category
- Rapastinel
- subject has role
- nootropic
Sources (1)
via Wikidata · CC0
~4 min read
Encyclopedic overview
7 sectionsContents
- Clinical development
- Pharmacology
- Preclinical research
- History
- See also
- References
- External links
Rapastinel () (former developmental code name GLYX-13) is a novel antidepressant that was under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant depression. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide that acts as a novel and selective modulator of the NMDA receptor. The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to enhance NMDA receptor-mediated signal transduction and synaptic plasticity.
== Clinical development ==
Excerpted from Wikipedia’s “rapastinel” article, available under the CC BY-SA 4.0 licence.